VRDN insider buying – Viridian Therapeutics, Inc.\DE
11 insider purchases since 2016 worth $93.1M by 8 different insiders. Last 12 months: 1 purchases, $20.0M. Most recent filing: 2026-05-13.
Same time range as the chart above - each mark sits under the week of the trade. Circles = purchases (height = price paid, size = amount), red triangles = open-market sales of $50k+. Prices as reported, not adjusted for later stock splits.
Purchases are open-market buys (SEC Form 4, code "P") - insiders paying with their own money. Sales are open-market sales (code "S") of $50,000 or more; many sales are pre-planned (Rule 10b5-1) or made for taxes and diversification. Each row links to the original filing.
Bought, sold, still holding?
| Insider | Bought | First / last buy | Sold since 2016 | Holds now* | Status |
|---|---|---|---|---|---|
| Fairmount Healthcare Fund II L.P. Director | $60.0M 3× · 3,252,660 sh | 2024-01-22 2026-05-11 | – | 5,090,928 shares as of 2026-05-13 | Holds - never sold |
| Fairmount Healthcare Fund II GP LLC Director | $10.0M 1× · 454,545 sh | 2025-10-23 2025-10-23 | – | 3,914,458 shares as of 2025-10-27 | Holds - never sold |
| Fairmount Healthcare Fund GP LLC Director | $10.0M 1× · 425,531 sh | 2022-08-17 2022-08-17 | – | 1,369,623 shares as of 2022-08-19 | Holds - never sold |
| Fairmount Healthcare Fund L.P. Director | $10.0M 1× · 909,000 sh | 2021-09-21 2021-09-21 | – | 944,092 shares as of 2021-09-23 | Holds - never sold |
| Frazier Life Sciences Public Fund, L.P. 10% Owner | $2.2M 1× · 200,000 sh | 2021-09-23 2021-09-23 | – | 1,505,200 shares as of 2021-09-28 | Holds - never sold |
| Mahoney Stephen F. CEO | $499,262 1× · 21,400 sh | 2024-09-27 2024-09-27 | – | 33,349 shares as of 2026-03-09 | Holds - never sold |
| Myers Scott Dunseth CEO | $261,805 2× · 9,500 sh | 2023-03-13 2023-04-12 | – | 259,500 shares as of 2023-04-12 | Holds - never sold |
| Beetham Thomas W. Officer | $117,050 1× · 5,000 sh | 2024-09-27 2024-09-27 | – | 13,361 shares as of 2026-03-09 | Holds - never sold |
* Shares held after the insider's most recent SEC filing for this company (all share classes, direct and indirect). If an insider stops filing, later changes are not known.
Insider buying and selling by year
| Year | Purchases | Bought | Buyers | Sales | Sold |
|---|---|---|---|---|---|
| 2026 | 1 | $20.0M | 1 | 2 | $418,990 |
| 2025 | 1 | $10.0M | 1 | – | – |
| 2024 | 4 | $40.6M | 3 | – | – |
| 2023 | 2 | $261,805 | 1 | 7 | $6.4M |
| 2022 | 1 | $10.0M | 1 | 8 | $3.6M |
| 2021 | 2 | $12.2M | 2 | – | – |
Insider purchases
| Filed | Insider | Role | Shares | Avg price | Value | Holdings | Filing |
|---|---|---|---|---|---|---|---|
| 2026-05-13 | Fairmount Healthcare Fund II L.P. | Director | 1,176,470 | $17.00 | $20.0M | +30.1% | SEC |
| 2025-10-27 | Fairmount Healthcare Fund II GP LLC | Director | 454,545 | $22.00 | $10.0M | +13.1% | SEC |
| 2024-09-30 | Mahoney Stephen F. | CEO | 21,400 | $23.33 | $499,262 | SEC | |
| 2024-09-30 | Beetham Thomas W. | Officer | 5,000 | $23.41 | $117,050 | +500.0% | SEC |
| 2024-09-17 | Fairmount Healthcare Fund II L.P. | Director | 1,600,000 | $18.75 | $30.0M | +86.7% | SEC |
| 2024-01-24 | Fairmount Healthcare Fund II L.P. | Director | 476,190 | $21.00 | $10.0M | +34.9% | SEC |
| 2023-04-12 | Myers Scott Dunseth | CEO | 4,000 | $25.37 | $101,480 | +1.6% | SEC |
| 2023-03-13 | Myers Scott Dunseth | CEO | 5,500 | $29.15 | $160,325 | +2.2% | SEC |
| 2022-08-19 | Fairmount Healthcare Fund GP LLC | Director | 425,531 | $23.50 | $10.0M | +45.4% | SEC |
| 2021-09-28 | Frazier Life Sciences Public Fund, L.P. | 10% Owner | 200,000 | $11.00 | $2.2M | +15.3% | SEC |
| 2021-09-23 | Fairmount Healthcare Fund L.P. | Director | 909,000 | $11.00 | $10.0M | +3109.5% | SEC |
Insider sales
| Filed | Insider | Role | Shares | Avg price | Value | Type | Filing |
|---|---|---|---|---|---|---|---|
| 2026-08-20 | Tousignant Jennifer | Officer | 14,212 | $24.50 | $348,194 | Sale | SEC |
| 2026-01-02 | Tousignant Jennifer | Officer | 2,272 | $31.16 | $70,796 | Sale | SEC |
| 2023-06-20 | Meisner Lara | Officer | 2,296 | $28.02 | $64,343 | Sale | SEC |
| 2023-06-06 | Meisner Lara | Officer | 7,500 | $24.82 | $186,136 | Pre-planned (10b5-1) | SEC |
| 2023-03-10 | Meisner Lara | Officer | 29,971 | $29.07 | $871,257 | Sale | SEC |
| 2023-02-03 | Violin Jonathan | Officer | 50,000 | $36.80 | $1.8M | Sale | SEC |
| 2023-01-25 | Meisner Lara | Officer | 6,843 | $35.66 | $244,021 | Sale | SEC |
| 2023-01-18 | Katz Barrett | Officer | 29,000 | $37.18 | $1.1M | Sale | SEC |
| 2023-01-11 | Katz Barrett | Officer | 60,000 | $34.82 | $2.1M | Sale | SEC |
| 2022-12-22 | Meisner Lara | Officer | 16,926 | $29.15 | $493,398 | Sale | SEC |
| 2022-12-14 | Meisner Lara | Officer | 16,256 | $28.12 | $457,077 | Sale | SEC |
| 2022-11-16 | Meisner Lara | Officer | 8,125 | $22.05 | $179,156 | Sale | SEC |
| 2022-06-02 | Violin Jonathan | Officer | 30,000 | $12.20 | $366,000 | Sale | SEC |
| 2022-05-04 | Violin Jonathan | CEO | 30,000 | $13.04 | $391,200 | Sale | SEC |
| 2022-04-05 | Violin Jonathan | Officer | 30,000 | $18.92 | $567,636 | Sale | SEC |
Showing the latest 15 of 17 sales of $50,000+ since 2016.
Compiled automatically from public SEC filings. Not investment advice. Get every new insider purchase in the daily report.
Get every new insider purchase the day it's filed
Daily report with all SEC insider buys, cluster buys, company events and the crypto money-flow radar.
Get started free